{
    "nct_id": "NCT02955394",
    "official_title": "Randomized Phase II Trial of Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer",
    "inclusion_criteria": "* ER+ Her2- breast cancer\n* Stage at least T2 or greater\n* Planned to get local surgery\n* Postmenopausal, or if pre- or peri- menopausal, then will need to have concurrent ovarian suppression.\n* At least 18 years of age\n* Not on anticoagulants\n* PS 0-2\n* Able to swallow study drug and comply with study requirements\n* ANC >1000/uL, platelets >75,000/uL at screening visit\n* Total bilirubin < 1.5 times upper limit of normal (ULN) at the screening visit unless an alternate nonmalignant etiology exists (eg, Gilbert's disease)\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 times ULN or < 5 times ULN if patient has documented liver metastases\n* Creatinine < 1.5 times ULN\n* INR < 1.5 times ULN, or if on warfarin, can safely transition off for biopsy\n* Willing to donate blood for research at 4 time points\n* Willing to undergo core biopsies for research at study entry and at ~4 weeks.\n* Willing to donate tissue to research from the surgical specimen\n* Written informed consent obtained prior to biopsies and blood samples\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 101 Years",
    "exclusion_criteria": "* Current or previously treated brain or leptomeningeal metastases\n* History of seizures\n* Prior treatment with an anti-androgen (abiraterone, ARN-509, bicalutamide, enzalutamide, ODM-201, TAK-448, TAK-683, TAK-700, VT-464).\n* Systemic estrogens or androgens within 14 days before initiating therapy. Vaginal estrogens are allowed if necessary for patient comfort.",
    "miscellaneous_criteria": ""
}